Levosimendan Stada

Levosimendan, the active ingredient in Levosimendan Stada, is a calcium sensitizer presented as an injection for intravenous use. It improves cardiac contractility in adults with acute decompensated heart failure by sensitizing troponin C to calcium and opening ATP‑sensitive potassium channels, which also produce vasodilation and support hemodynamic stability.

GNH USA supplies Levosimendan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing reliable access to this specialized cardiovascular therapy for qualified healthcare institutions. The company follows Good Distribution Practice, ensures temperature‑controlled logistics, and offers regulatory support to facilitate importation and clinical use across diverse international markets.

Levosimendan is indicated for conditions involving acute cardiac dysfunction where enhanced contractility and vasodilation are required.

- Acute decompensated heart failure: improves symptoms and hemodynamic parameters in hospitalized adults. - Severe chronic heart failure (bridge therapy): provides temporary inotropic support while definitive treatment is optimized. - Low cardiac output syndrome after cardiac surgery: assists in stabilizing circulation during postoperative recovery.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure causing dizziness. - Headache: mild to moderate cranial pain. - Nausea: gastrointestinal upset.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Severe hypotension: profound blood pressure fall requiring intervention.

Levosimendan requires careful monitoring and specific safety measures before and during administration.

- Cardiovascular monitoring: continuous blood pressure and ECG observation during infusion. - Concomitant vasodilators: avoid or reduce dose to prevent excessive hypotension. - Electrolyte balance: correct potassium and magnesium before administration. - Renal impairment: adjust infusion rate and monitor renal function. - Hepatic impairment: use with caution in patients with severe liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes; some combinations should be avoided while others need close observation.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase levosimendan exposure. - Other calcium sensitizers: additive inotropic effect leading to severe hypotension. - Concurrent potent vasodilators (e.g., nitroprusside): risk of profound blood pressure drop.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate electrolyte disturbances and hypotension. - Beta‑blockers: may blunt desired inotropic response. - ACE inhibitors or ARBs: monitor blood pressure and renal function.